SEC Form 4	
------------	--

## FORM 4

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to	SIALEMENI
Section 16. Form 4 or Form 5	
obligations may continue. See	
Instruction 1(b).	Filed purs

# STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

					01.5	ection	11 30(11)	oruie	investment	. Con	iipaily Ac	101 1940								
1. Name and Address of Reporting Person* Bolte Axel						2. Issuer Name <b>and</b> Ticker or Trading Symbol IVERIC bio, Inc. [ ISEE ]								(Ch	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
(Last)	(F	irst)	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 05/17/2023									X Direct Office below	r (give title		10% Ov Other (s below)		
C/O IVERIC BIO, INC.						4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable						
8 SYLVAN WAY															Line)					
(Street)															X Form filed by One Reporting Person Form filed by More than One Reporting Person					
PARSIP	PANY N	J	07054			Rule 10b5-1(c) Transaction Indication														
(City)	(S	tate)	(Zip)			Check	this box	c to inc	dicate that a t	ransa	action was	made pur	suant t	o a coi	ntract, instruc	tion or writte	n plan	n that is intend	ded to	
							Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.													
		Tabl	e I - Nor	ו-Deriv	ative	Sec	urities	s Ac	quired, I	Disp	osed	of, or E	Bene	ficia	lly Owne	d				
1. Title of Security (Instr. 3) Date (Month/E					Execution I			Transaction Dispose Code (Instr. 5)		urities Acquired (A sed Of (D) (Instr. 3,			d Securiti Benefic Owned	eficially ed Following		n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership			
									Code	v	Amount (A) or (D)		Price		rted action(s) 3 and 4)			(Instr. 4)		
		Ta							uired, Di s, option						y Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deem Executior if any (Month/D	Date, Transa Code (		saction le (Instr. be (Instr. be (Instr.) be (Cartifies acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		tive ties red sed 3, 4	6. Date Exe Expiration (Month/Day		e and Amount of Securities Underlying Derivative Sect (Instr. 3 and 4)			8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transactio (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Naturn of Indirec Beneficia Ownershi (Instr. 4)		
					Code	v	(A)	(D)	Date Exercisable		<piration ate<="" th=""><th>Title</th><th>or Nu of</th><th>iount mber ares</th><th></th><th></th><th></th><th></th><th></th></piration>	Title	or Nu of	iount mber ares						
Restricted Stock Units	(1)	05/17/2023			Α		7,500		(2)		(2)	Commor Stock	<sup>1</sup> 7,	500	\$0	7,500		D		

### Explanation of Responses:

1. Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit.

2. Subject to the Reporting Person providing continued services to the Registrant and other terms and conditions under the Registrant's 2023 Stock Incentive Plan, the award of restricted stock units will vest in full on the earlier of one business day prior to the Registrant's 2024 annual meeting of stockholders or the first anniversary of the grant date. Any unvested shares subject to the award of restricted stock units will be accelerated in full upon the occurrence of a change in control event (as defined in the Registrant's 2023 Stock Incentive Plan). For purposes of this report on Form 4, a change in control event includes the closing of the transaction contemplated by the Agreement and Plan of Merger, dated April 28, 2023, between the Registrant, Astellas US Holding, Inc., Berry Merger Sub, Inc. and solely as provided by Section 8.10(b) of such agreement, Astellas Pharma Inc.

### **Remarks:**

/s/ Todd D.C. Anderman, as Attorney-in-Fact for Axel Bolte

05/19/2023

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.